GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Divi's Laboratories Ltd (NSE:DIVISLAB) » Definitions » ROE % Adjusted to Book Value

Divi's Laboratories (NSE:DIVISLAB) ROE % Adjusted to Book Value : 0.00% (As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Divi's Laboratories ROE % Adjusted to Book Value?

Divi's Laboratories's ROE % for the quarter that ended in Dec. 2023 was 11.45%. Divi's Laboratories's PB Ratio for the quarter that ended in Dec. 2023 was N/A. Divi's Laboratories's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was N/A.


Divi's Laboratories ROE % Adjusted to Book Value Historical Data

The historical data trend for Divi's Laboratories's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Divi's Laboratories ROE % Adjusted to Book Value Chart

Divi's Laboratories Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.23 2.67 2.31 2.83 2.54

Divi's Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 1.66 - 1.39 -

Competitive Comparison of Divi's Laboratories's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Divi's Laboratories's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Divi's Laboratories's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Divi's Laboratories's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Divi's Laboratories's ROE % Adjusted to Book Value falls into.



Divi's Laboratories ROE % Adjusted to Book Value Calculation

Divi's Laboratories's ROE % Adjusted to Book Value for the fiscal year that ended in Mar. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=14.89% / 5.87
=2.54%

Divi's Laboratories's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=11.45% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Divi's Laboratories ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Divi's Laboratories's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Divi's Laboratories (NSE:DIVISLAB) Business Description

Traded in Other Exchanges
Address
Divi Towers, 1-72/23(P)/DIVIS/303, Babukhan Lane, Cyber Hills, Gachibowli, Hyderabad, TG, IND, 500032
Divi's Laboratories Ltd is a specialty and generic drug manufacturing company. Most of the company's sales are generated in Europe, followed by North America, India, and Asia. The company has three distinct business segments: Generic APIs, Custom Synthesis, and Nutraceuticals. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Divi's Laboratories (NSE:DIVISLAB) Headlines

No Headlines